ClinicalTrials.Veeva

Menu

Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients

A

Amany Aboalenen Amin

Status

Unknown

Conditions

Hepatocellular Carcinoma

Treatments

Diagnostic Test: CBC

Study type

Observational

Funder types

Other

Identifiers

NCT03869151
17200000

Details and patient eligibility

About

To assess the prognostic role of pretreatment LMR in hepatocellular carcinoma(HCC).

Full description

The exact molecular mechanisms responsible for the prognostic impact of lymphocyte monocyte ratio in Heatocellular carcinoma are unclear.It has been suggested that cross-talk between the inflammatory response and tumor progression play a critical role in the initiation and progression of Heatocellular carcinoma. In the tumor microenvironment, inflammatory infiltrates have a large influence on the biological behavior of Heatocellular carcinoma.

Tumor-infiltrating lymphocytes, as representative component of the immune microenvironment ,are implicated in several stages of Heatocellular carcinoma progression, and Tumor-infiltrating lymphocytes phenotypes may be a predictor for favorable prognosis.

Conversely, low lymphocyte counts might result in an insufficient immunological reaction, which lead to inferior survival in multiple cancers.

Monocytes infiltrating tumor tissue are also involved in Heatocellular carcinoma development and progression. Activated monocytes in Heatocellular carcinoma micro environments can trigger and polarize T-cell responses and facilitate inflammation-induced tumor development.

Tumor-associated macrophages are derived from circulating monocytes. Tumor-associated macrophages can accelerate Heatocellular carcinoma cell proliferation,tumor-associated angiogenesis, and metastasis. Several studies showed that high infiltration of Tumor-associated macrophages predicted decreased survival in various cancers.

Enrollment

1 estimated patient

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with child A Hepatocellular carcinoma.

Exclusion criteria

  • Patients with child C Hepatocellular carcinoma.
  • Patients with heart failure

Trial contacts and locations

0

Loading...

Central trial contact

amany Amin, master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems